GOSS Logo

Gossamer Bio, Inc. (GOSS) 

NASDAQ$1.45
Market Cap
$328.58M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
203 of 924
Rank in Industry
120 of 527

GOSS Insider Trading Activity

GOSS Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$324,442333
Sells
$53,578667

Related Transactions

Hasnain FaheemPresident & CEO1$250,2821$26,773$223,509
Giraudo BryanCOO/CFO1$59,1101$7,431$51,679
Smith Robert Paul JRChief Commercial Officer1$15,0500$0$15,050
Peterson CarynEVP, Regulatory Affairs0$01$5,343$-5,343
Aranda RichardChief Medical Officer0$02$6,602$-6,602
Christian WaageEVP, Tech Ops and Admin0$01$7,430$-7,430

About Gossamer Bio, Inc.

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel â€¦

Insider Activity of Gossamer Bio, Inc.

Over the last 12 months, insiders at Gossamer Bio, Inc. have bought $324,442 and sold $53,578 worth of Gossamer Bio, Inc. stock.

On average, over the past 5 years, insiders at Gossamer Bio, Inc. have bought $969,539 and sold $287,158 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Hasnain Faheem (President & CEO) — $250,282. Giraudo Bryan (COO/CFO) — $59,110. Smith Robert Paul JR (Chief Commercial Officer) — $15,050.

The last purchase of 372,000 shares for transaction amount of $250,282 was made by Hasnain Faheem (President & CEO) on 2024‑06‑21.

List of Insider Buy and Sell Transactions, Gossamer Bio, Inc.

2024-06-24SaleAranda RichardChief Medical Officer
1,908
0.0007%
$0.66$1,260+12.58%
2024-06-21PurchaseHasnain FaheemPresident & CEO
372,000
0.2168%
$0.67$250,282+43.08%
2024-06-18PurchaseGiraudo BryanCOO/CFO
100,000
0.0512%
$0.59$59,110+71.42%
2024-06-17PurchaseSmith Robert Paul JRChief Commercial Officer
25,000
0.013%
$0.60$15,050+78.73%
2024-03-27SaleChristian WaageEVP, Tech Ops and Admin
6,430
0.0028%
$1.16$7,430-22.33%
2024-03-27SaleHasnain FaheemPresident & CEO
23,172
0.0101%
$1.16$26,773-22.33%
2024-03-27SaleGiraudo BryanCOO/CFO
6,430
0.0028%
$1.16$7,431-22.33%
2024-03-18SaleAranda RichardChief Medical Officer
4,018
0.0017%
$1.33$5,342-34.02%
2024-03-18SalePeterson CarynEVP, Regulatory Affairs
4,018
0.0017%
$1.33$5,343-34.02%
2023-11-15PurchaseMilligan Sandradirector
32,000
0.0139%
$0.79$25,213+11.07%
2023-11-13PurchaseGiraudo BryanCOO/CFO
200,000
0.0795%
$0.56$112,880+43.00%
2023-06-22SaleAranda RichardChief Medical Officer
1,814
0.0018%
$1.29$2,340-34.61%
2023-04-04PurchaseGiraudo BryanCOO/CFO
55,000
0.0583%
$1.02$56,095+3.96%
2023-03-16SaleAranda RichardChief Medical Officer
7,563
0.0083%
$1.10$8,3040.00%
2023-03-16SaleCarter LauraChief Scientific Officer
6,029
0.0066%
$1.10$6,6200.00%
2023-03-16SalePeterson CarynEVP, Regulatory Affairs
7,564
0.0083%
$1.10$8,3050.00%
2022-10-24SaleAranda RichardChief Medical Officer
4,757
0.0056%
$12.07$57,431-88.98%
2022-10-24SaleCarter LauraChief Scientific Officer
4,876
0.0058%
$12.07$58,868-88.98%
2022-10-24SalePeterson CarynEVP, Regulatory Affairs
4,757
0.0056%
$12.07$57,431-88.98%
2022-07-15PurchaseHasnain FaheemPresident & CEO
138,696
0.099%
$7.21$999,998-79.92%
Total: 62
*Gray background shows transactions not older than one year

Insider Historical Profitability

<0.0001%
Hasnain FaheemPresident & CEO
5408073
2.3866%
$7.84M42<0.0001%
Christian WaageEVP, Tech Ops and Admin
585934
0.2586%
$849,604.3043<0.0001%
Giraudo BryanCOO/CFO
480010
0.2118%
$696,014.5093+0.58%
Smith Robert Paul JRChief Commercial Officer
25000
0.011%
$36,250.0010
Gujrathi SheilaPresident & CEO
4048242
1.7865%
$5.87M10<0.0001%
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$99,438,720
81
6.74%
$290.44M
$5,911,307
70
-1.38%
$309.77M
$109,415,500
33
18.13%
$353.41M
$41,446,394
27
12.91%
$340.18M
$24,857,912
21
-35.40%
$287.11M

GOSS Institutional Investors: Active Positions

Increased Positions49+44.95%23M+13.38%
Decreased Positions40-36.7%27M-15.41%
New Positions18New2MNew
Sold Out Positions13Sold Out6MSold Out
Total Postitions118+8.26%171M-2.02%

GOSS Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Octagon Capital Advisors Lp$22,571.008.08%18.35M+9M+99.72%2024-12-31
Nea Management Company, Llc$22,254.007.97%18.09M00%2024-12-31
Vanguard Group Inc$12,342.004.42%10.03M-2M-14.63%2024-12-31
Alyeska Investment Group, L.P.$10,834.003.88%8.81M+3M+52.73%2024-12-31
Arch Venture Management, Llc$9,909.003.55%8.06M00%2024-12-31
Fmr Llc$9,758.003.5%7.93M-2,735-0.03%2024-12-31
683 Capital Management, Llc$8,579.003.07%6.97M+1M+20.26%2024-12-31
Palo Alto Investors Lp$7,721.002.77%6.28M00%2024-12-31
Silverarc Capital Management, Llc$7,591.002.72%6.17M+526,495+9.33%2024-12-31
Samsara Biocapital, Llc$7,540.002.7%6.13M00%2024-12-31

Financial Ratios

Summary
Comparison with Competitors

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.